Mineralys Therapeutics Future Growth
Future criteria checks 0/6
Mineralys Therapeutics's earnings are forecast to decline at 3.4% per annum while its annual revenue is expected to grow at 80.4% per year. EPS is expected to grow by 7.1% per annum.
Key information
-3.4%
Earnings growth rate
7.1%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 80.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
Oct 07
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Sep 17We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jun 06Mineralys Therapeutics: A Story To Keep An Eye On
Mar 18Mineralys: 2nd Half 2024 Hypertension Data Readout
Feb 09We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
Nov 12We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jul 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 56 | -209 | -220 | N/A | 4 |
| 12/31/2025 | N/A | -209 | -238 | N/A | 4 |
| 12/31/2024 | N/A | -179 | -209 | N/A | 4 |
| 9/30/2024 | N/A | -153 | -129 | -128 | N/A |
| 6/30/2024 | N/A | -120 | -97 | -97 | N/A |
| 3/31/2024 | N/A | -91 | -88 | -88 | N/A |
| 12/31/2023 | N/A | -72 | -81 | -81 | N/A |
| 9/30/2023 | N/A | -57 | -62 | -62 | N/A |
| 6/30/2023 | N/A | -40 | -50 | -50 | N/A |
| 3/31/2023 | N/A | -35 | -35 | -35 | N/A |
| 12/31/2022 | N/A | -30 | -29 | -29 | N/A |
| 9/30/2022 | N/A | -28 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -19 | -15 | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MLYS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MLYS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MLYS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MLYS is forecast to have no revenue next year.
High Growth Revenue: MLYS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MLYS's Return on Equity is forecast to be high in 3 years time